Northwest & Ethical Investments L.P. Buys Shares of 9,007 Cencora, Inc. $COR

Northwest & Ethical Investments L.P. bought a new position in Cencora, Inc. (NYSE:COR) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 9,007 shares of the company’s stock, valued at approximately $2,701,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Rhenman & Partners Asset Management AB increased its holdings in Cencora by 52.5% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 49,375 shares of the company’s stock worth $14,805,000 after buying an additional 17,000 shares in the last quarter. J.W. Cole Advisors Inc. boosted its holdings in shares of Cencora by 8.7% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 6,540 shares of the company’s stock valued at $1,961,000 after acquiring an additional 522 shares during the last quarter. Elo Mutual Pension Insurance Co boosted its holdings in shares of Cencora by 10.7% during the 2nd quarter. Elo Mutual Pension Insurance Co now owns 23,273 shares of the company’s stock valued at $6,978,000 after acquiring an additional 2,259 shares during the last quarter. Laurel Wealth Advisors LLC grew its stake in shares of Cencora by 29,900.0% in the second quarter. Laurel Wealth Advisors LLC now owns 900 shares of the company’s stock worth $270,000 after acquiring an additional 897 shares during the period. Finally, Aviso Financial Inc. raised its holdings in shares of Cencora by 16.7% during the second quarter. Aviso Financial Inc. now owns 10,231 shares of the company’s stock valued at $3,068,000 after purchasing an additional 1,462 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This trade represents a 7.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 46,640 shares of company stock valued at $14,099,338 over the last three months. 10.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on COR shares. TD Cowen raised their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. UBS Group increased their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wells Fargo & Company lifted their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Robert W. Baird increased their target price on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Trading Down 1.6%

Shares of COR stock opened at $368.64 on Thursday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The company has a market cap of $71.47 billion, a price-to-earnings ratio of 37.93, a PEG ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The firm has a fifty day moving average price of $332.58 and a 200-day moving average price of $306.37.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the firm earned $3.34 EPS. Cencora’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be paid a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.